KEYNOTE-C11
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- NCT05008224 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYNOTE-C11 (pembrolizumab plus AVD; pembrolizumab plus escBEACOPP in newly diagnosed classical Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-C11 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Pembrolizumab; Doxorubicin; Vinblastine; Dacarbazine; Bleomycin; Etoposide; Cyclophosphamide; Vincristine; Procarbazine; Prednisone
- Arms
- Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation · Experimental
- Enrollment
- 146
- Primary outcomes
- Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Oct 7, 2021
- Primary completion
- Oct 11, 2023
- Results posted
- Yes
- Registry record
- NCT05008224 · updated Jun 6, 2025